Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI study
Emicizumab provided bleed protection regardless of age and comorbidity. Clinical baseline characteristics did not predict breakthrough bleeding under emicizumab. Poor WHO-PS at baseline was associated with severe adverse events during the study.
Authors
- Ulrich J. Sachs (ORCID: https://orcid.org/0000-0001-5486-5542)
- Karolin Trautmann‐Grill (ORCID: https://orcid.org/0000-0002-9050-1049)
- Robert Klamroth (ORCID: https://orcid.org/0000-0003-4194-8183)
- Hermann Eichler (ORCID: https://orcid.org/0000-0002-1372-0619)
- Richard Greil (ORCID: https://orcid.org/0000-0002-4462-3694)
- Christian Pfrepper (ORCID: https://orcid.org/0000-0002-0485-7402)
- Patrick Möhnle (ORCID: https://orcid.org/0000-0003-4769-7100)
- Katharina Holstein (ORCID: https://orcid.org/0000-0003-3753-0972)
- Johannes Oldenburg (ORCID: https://orcid.org/0000-0002-1585-4100)
- Andreas Tiede (ORCID: https://orcid.org/0000-0002-3600-8536)
- Christiane Dobbelstein
- Wolfgang Miesbach (ORCID: https://orcid.org/0000-0002-4506-0061)
- Matthias Höpting
- Christian Herbert Burgmann
- Paul Knöbl
Institutions
- Goethe University Frankfurt (DE)
- Universität Hamburg (DE)
- Justus-Liebig-Universität Gießen (DE)
- Paracelsus Medical University (AT)
- University Hospital Regensburg (DE)
- Medizinische Hochschule Hannover (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital Leipzig (DE)
- Cellular Therapeutics (United Kingdom) (GB)
- Klinikum im Friedrichshain (DE)
- University Hospital Carl Gustav Carus (DE)
- Medical University of Vienna (AT)
- Ludwig-Maximilians-Universität München (DE)
- Saarland University (DE)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1016/j.rpth.2024.102565
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- American Heart Association